Reduced circulating CD4+CD25+ cell populations in Guillain–Barré syndrome
暂无分享,去创建一个
[1] R. Hughes,et al. Guillain-Barré syndrome , 1994, The Lancet.
[2] Y. Shinohara,et al. Natural killer cells in patients with Guillain-Barré syndrome , 1998, Journal of the Neurological Sciences.
[3] H. Wekerle,et al. Morphologic study on experimental allergic neuritis mediated by T cell line specific for bovine P2 protein in Lewis rats. , 1985, Laboratory investigation; a journal of technical methods and pathology.
[4] M. Toda,et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. , 1998, International immunology.
[5] J. Alcocer-Varela,et al. Quantification of regulatory T cells in patients with systemic lupus erythematosus. , 2003, Journal of autoimmunity.
[6] R. Hughes,et al. The distribution of CD1 molecules in inflammatory neuropathy , 1998, Journal of the Neurological Sciences.
[7] Clare Baecher-Allan,et al. Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis , 2004, The Journal of experimental medicine.
[8] R. Hughes,et al. A prospective study of acute idiopathic neuropathy. II. Antecedent events. , 1988, Journal of neurology, neurosurgery, and psychiatry.
[9] J. Ernerudh,et al. T lymphocyte subset abnormalities in peripheral blood from patients with the Guillain-Barré syndrome , 1994, Journal of Neuroimmunology.
[10] H. Hartung,et al. Serum interleukin‐2 concentrations in Guillain‐Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: Comparison with other neurological diseases of presumed immunopathogenesis , 1991, Annals of neurology.
[11] Nigel J. Saunders,et al. CD4+CD25+ TR Cells Suppress Innate Immune Pathology Through Cytokine-dependent Mechanisms , 2003, The Journal of experimental medicine.
[12] P. Krammer,et al. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis , 2005, European journal of immunology.
[13] A. Fattorossi,et al. Circulating and thymic CD4+ CD25+ T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment , 2005, Immunology.
[14] H. Hartung,et al. Inflammatory infiltrates in sural nerve biopsies in Guillain‐Barré syndrome and chronic inflammatory demyelinating neuropathy , 1996, Muscle & nerve.
[15] W. Kuis,et al. CD4+CD25bright Regulatory T Cells Actively Regulate Inflammation in the Joints of Patients with the Remitting Form of Juvenile Idiopathic Arthritis , 2004, The Journal of Immunology.
[16] H. Ochs,et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 , 2001, Nature Genetics.
[17] A. Rudensky,et al. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.
[18] D. Vergani,et al. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. , 2004, Journal of hepatology.
[19] F. Yoshii,et al. Impaired interleukin‐2 response of mononuclear cells in Guillain–Barré syndrome , 2000, European journal of neurology.
[20] M. Honavar,et al. A clinicopathological study of the Guillain-Barré syndrome. Nine cases and literature review. , 1991, Brain : a journal of neurology.
[21] H. Hartung,et al. Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcome , 1998, Annals of neurology.
[22] S. Sakaguchi,et al. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation , 1996, The Journal of experimental medicine.
[23] M. Roncarolo,et al. Human Cd25+Cd4+ T Regulatory Cells Suppress Naive and Memory T Cell Proliferation and Can Be Expanded in Vitro without Loss of Function , 2001, The Journal of experimental medicine.
[24] M. Toda,et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.
[25] G. Mckhann,et al. Differential Distribution of HLA-DQβ/DRβ Epitopes in the Two Forms of Guillain-Barré Syndrome, Acute Motor Axonal Neuropathy and Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Identification of DQβ Epitopes Associated with Susceptibility to and Protection from AIDP1 , 2003, The Journal of Immunology.
[26] S. Kremlev,et al. Flow cytometric analysis of infiltrating cells in the peripheral nerves in experimental allergic neuritis , 2000, Journal of Neuroimmunology.
[27] S. Cook,et al. Clinical correlation with serum‐soluble interleukin‐2 receptor levels in Guillain‐Barré syndrome , 1991, Neurology.
[28] G. Schuler,et al. Ex Vivo Isolation and Characterization of Cd4+Cd25+ T Cells with Regulatory Properties from Human Blood , 2001, The Journal of experimental medicine.
[29] R. Hughes,et al. CONTROLLED TRIAL OF PREDNISOLONE IN ACUTE POLYNEUROPATHY , 1978, The Lancet.
[30] R. Lechler,et al. Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease. , 2003, Kidney international.
[31] H. Hartung,et al. Expression and distribution of transcription factor NF-κB and inhibitor IκB in the inflamed peripheral nervous system , 2001, Journal of Neuroimmunology.
[32] H. Hartung,et al. T cell activation in Guillain‐Barré syndrome and in MS , 1990, Neurology.
[33] R. Adams,et al. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. , 1969, Medicine.
[34] R. Hughes,et al. Guillain-Barré syndrome. , 1994, Lancet.
[35] D. Cornblath,et al. Assessment of current diagnostic criteria for Guillain‐Barré syndrome , 1990, Annals of neurology.
[36] R. Hughes,et al. T lymphocyte activation antigens in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy , 1989, Journal of Neuroimmunology.
[37] A. Enk,et al. Identification and Functional Characterization of Human Cd4+Cd25+ T Cells with Regulatory Properties Isolated from Peripheral Blood , 2001, The Journal of experimental medicine.
[38] Svetlana Ten,et al. Multiple immuno-regulatory defects in type-1 diabetes. , 2002, The Journal of clinical investigation.
[39] D. Orlikowski,et al. Monocyte chemoattractant protein 1 and chemokine receptor CCR2 productions in Guillain–Barré syndrome and experimental autoimmune neuritis , 2003, Journal of Neuroimmunology.
[40] J K Nicholson,et al. Use of CD45 fluorescence and side-scatter characteristics for gating lymphocytes when using the whole blood lysis procedure and flow cytometry. , 1996, Cytometry.
[41] L. Klareskog,et al. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease , 2004, Arthritis research & therapy.
[42] F. Yoshii,et al. Lymphocyte Subset Proportions in Guillain-Barré Syndrome Patients Treated with Plasmapheresis , 2000, European Neurology.
[43] J. Casanova,et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy , 2001, Nature Genetics.
[44] H. Wekerle,et al. A permanent rat T cell line that mediates experimental allergic neuritis in the Lewis rat in vivo. , 1984, Journal of immunology.
[45] C. Brosnan,et al. Phenotypic and functional properties of γδ T Cells from patients with Guillain Barré syndrome , 2000, Journal of Neuroimmunology.
[46] Clare Baecher-Allan,et al. MHC Class II Expression Identifies Functionally Distinct Human Regulatory T Cells1 , 2006, The Journal of Immunology.
[47] A. Scheffold,et al. Regulation of CD4+CD25+ regulatory T cell activity: it takes (IL‐)two to tango , 2005, European journal of immunology.
[48] J. Malin,et al. A longitudinal study of circulating lymphocyte subsets in the peripheral blood during the acute stage of Guillain-Barré syndrome , 1997, Journal of the Neurological Sciences.